Pfizer’s Q2 Earnings Surge Sparks Investor Interest Amid Stock Slump

Pfizer Inc. (PFE) shares, once a pandemic darling, have languished in recent years as demand for its COVID-19 vaccine waned. The stock's decline has been precipitous, shedding more than half its value since 2023 and hitting 13-year lows. Despite the steep drop, investor enthusiasm remains tepid, clouded by uncertainty over the company's growth trajectory.

The pharmaceutical giant's second-quarter earnings report for 2025 offered a glimmer of hope. Revenue climbed 10% year-over-year to $14.7 billion, handily surpassing analyst estimates of $13.6 billion. Adjusted earnings per share of $0.78 crushed expectations of $0.58. The company also raised its full-year guidance, signaling confidence in its recovery.

Market watchers now debate whether this marks an inflection point for the beleaguered stock. With valuations at historic lows and operational performance showing signs of stabilization, Pfizer presents a compelling risk-reward proposition for contrarian investors.